Phase 3 Colorectal Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 to 65 years who are willing to give their consent to take part in the study.
• People who have been diagnosed with colon cancer and are planned to receive standard chemotherapy for at least 3 cycles.
• People whose colon cancer diagnosis has been confirmed following standard medical guidelines.
• People who have a general health and activity level rated between 0 and 2 on a standard medical scale, meaning they are able to carry out daily activities at least some of the time (confirm with trial site).
• People whose haemoglobin (a measure of red blood cells) is at least 9 g/dL and has remained steady during the screening period.
• People who, in the opinion of the treating doctor, are expected to live for at least 6 months.
• People who have other health conditions such as Type 2 diabetes or high blood pressure, provided the treating doctor considers these conditions to be stable.
• People who have stable tiredness, newly developed tiredness, or worsening tiredness as measured by a standard fatigue assessment tool called the Brief Fatigue Inventory (BFI).
• People who are starting their first course of chemotherapy treatment.

Who may not be able to join:

• People who have an untreated medical condition that could be causing tiredness, such as an infection, hormone disorder, or metabolic problem.
• People whose colon cancer has reached Stage IV (the most advanced stage).
• People who are taking stimulant medications (such as dextroamphetamine or methylphenidate) during the screening period, or any medication that could interact with the study drug.
• People who have previously received chemotherapy, targeted therapy, or immunotherapy for cancer that had spread to other parts of the body, or who have serious other health conditions.
• People who are pregnant or currently breastfeeding.
• People with a known infection of hepatitis B, hepatitis C, or HIV.
• People who have severe nausea, vomiting, or a digestive condition that the treating doctor believes would prevent the study drug from being properly absorbed.
• People whose pain is not well controlled and who the treating doctor does not consider suitable for the study.
• People who are planning to take part in another clinical trial at the same time.
• People who have taken part in another clinical trial or received an investigational drug within the 4 weeks before screening, or who plan to do so during this study.

Important: Always verify eligibility with the trial site directly before applying.